Psychiatry

Back to articles

Zaleplon: Short Duration of Action, Long-Term Effectiveness

KEY POINT

Although approved by FDA for short-term therapy (7–10 days), the new hypnotic agent zaleplon (Sonata—Wyeth-Ayerst) is safe and well tolerated when used to treat insomnia for longer time periods. Patients have not thus far experienced any withdrawal syndrome upon drug discontinuation, regardless of the length of therapy.

SOURCES

Scharf M et al. Paper presented to the European College of Neuropsychopharmacology, London, 1999 Sept.

Kirkwood CK. Management of insomnia. J Am Pharm Assoc. 1999;39:688–96.